Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
German-Polish man charged with calling for attacks on top politicians - 2Major railway disruptions persist as Germany braces for more snow
- 3Rights group: At least 2,500 deaths during protest crackdown in Iran
- 4Vote in favor of Your Fantasy Vehicle: Which Notable Model Catches Your Heart?
- 5Bullets in Luigi Mangione’s bag convinced police that he was UnitedHealthcare CEO killing suspect
- Gen Z workplace stereotypes were TV’s favorite punchline in 2025
- Chinese mega embassy could bring security advantages, says No 10
- German finance minister sees advantages of smartphones in schools
- The most effective method to Alter Your Savvy Bed for A definitive Rest Insight
- Thousands of New York City nurses set to strike Monday if deal isn't reached with hospitals
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
- Figure out How to Keep up with Oral Wellbeing During Pregnancy
- Nestlé recalls infant formula in 49 countries. See list.
- Minute Maid’s frozen juice concentrate is ending after 80 years — and so is a certain kind of kitchen ritual
